To improve the lives of patients and surgeons by inventing and developing effective and safe treatments for unmet medical needs in the ocular markets, starting with Acute Ocular Pain (AOP).

To build a pipeline of innovative ophthalmic opportunities that will enable more patients to feel comfortable in treating their ocular diseases and improve surgical outcomes.

T6030 is formulated using a reprofiled well-characterized drug, which has been approved and marketed in its oral form for decades. It has a well established safety and efficacy profile, and T6030 in its topical ocular form does not have concerns for dependency, side effects or abuse.